Exposure to inhibitors of the renin–angiotensin system is a major independent risk factor for acute renal failure induced by sucrose‐containing intravenous immunoglobulins: a case–control study

Risk factors for intravenous immunoglobulin‐induced renal failure (IVIg‐RF) were suspected from case series studies. This study was aimed at quantifying the risk of IVIg‐RF associated with exposure to drugs that modify intrarenal hemodynamics.

[1]  A. Akram,et al.  Incidence and prognostic implications of acute kidney injury on admission in patients with community-acquired pneumonia. , 2010, Chest.

[2]  Michael L. Bentley,et al.  Drug-induced acute kidney injury in the critically ill adult: Recognition and prevention strategies , 2010, Critical care medicine.

[3]  G. Breithardt,et al.  Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  R. Ranjan,et al.  Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[5]  M. Devita,et al.  The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy , 2008, International Urology and Nephrology.

[6]  L. Pupim,et al.  Angiotensin-Converting Enzyme Inhibitors as a Risk Factor for Contrast-Induced Nephropathy , 2006, Nephron Clinical Practice.

[7]  S. Chapman,et al.  Acute Renal Failure and Intravenous Immune Globulin: Occurs with Sucrose-Stabilized, but Not with D-Sorbitol–Stabilized, Formulation , 2004, The Annals of pharmacotherapy.

[8]  Y. Shoenfeld,et al.  Intravenous immunoglobulin and the kidney--a two-edged sword. , 2004, Seminars in arthritis and rheumatism.

[9]  Samin K. Sharma,et al.  Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. , 2002, The American journal of cardiology.

[10]  H. Watson,et al.  Incidence and associations of acute renal failure complicating high‐dose intravenous immunoglobulin therapy , 2001, British journal of haematology.

[11]  G. Decocq,et al.  Acute renal failure associated with intravenous immunoglobulins , 1999, Pharmacoepidemiology and drug safety.

[12]  F. Peyrade,et al.  Insuffisance rénale aiguë aux immunoglobulines , 1998 .

[13]  G. Bernardi,et al.  Muscle phosphofructokinase deficiency , 1997, Neurology.

[14]  N. Moore,et al.  [French pharmacovigilance database system: examples of utilisation]. , 1995, Therapie.

[15]  P. Kaminsky,et al.  [High dose intravenous immunoglobulins in therapeutic arsenal in autoimmune and systemic diseases]. , 1993, The´rapie (Paris).

[16]  B. Piraino,et al.  Pulmonary and renal toxicity of intravenous immunoglobulin. , 1991, Clinical nephrology.

[17]  G. Stone,et al.  Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. , 2005, The American journal of cardiology.

[18]  Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998. , 1999, MMWR. Morbidity and mortality weekly report.

[19]  F. Peyrade,et al.  [Acute renal failure due to immunoglobulins]. , 1998, La Revue de medecine interne.

[20]  J Jouglard,et al.  [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. , 1985, Therapie.